Interview with Dominique Demolle , Co-founder & CEO, Aepodia
Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what pharmaceutical companies need in an outsourcing…
Address: Avenue Albert Einstein 2A
1348 Louvain-la-Neuve
Belgium
Tel: +32 (0)10 39 20 11
Web: http://http/www.aepodia.com
Aepodia S.A. (spin-off of a top 10 US Pharma Company) was created in March 2007 by a group of experts in early-phase clinical development. Since then, our company has grown and built a strong and a worldwide reputation in the early clinical drug development sector. We have established solid and effective collaborations with world pharmaceutical leaders, as well as with small biotech companies. The management and staff members have a background in pharmaceutical development that allows us to understand sponsor requirements and challenges and to meet their needs in an optimal way.
Our headquarters are located in Louvain-La-Neuve, Belgium, with offices in Paris-La Défense, France. Thanks to our strategic location in the center of Europe, we can cover the European phase I units. We also support clinical trials in the United-States and Singapore and provide easy access to patients.
Aepodia is a CRO sponsor representative providing customized services in Phase I/II clinical trials and in clinical development of Medical devices.
Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what pharmaceutical companies need in an outsourcing…
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s…
Belgium is a vitally important country for Johnson & Johnson’s pharmaceutical arm, Janssen, globally. In addition to their R&D centre and a pharma production plant in Beerse, Janssen also has…
Belgian doctor, researcher and professor, Stéphane De Wit has been with the St Pierre University Hospital in Brussels since 1983. Initially planning to specialize in intensive care, his first internship…
Belgium’s healthcare system was ranked fourth in Europe in 2019, outperforming its peers across a number of metrics including a relatively high number of hospital beds per capita (six per…
Carl Laurent, managing director and CEO of Siemens Healthineers BeLux, sits down with PharmaBoardroom to explain Siemens Healthineers’ footprint and impact in Belgium and Luxembourg, the importance of appreciating diagnostics…
Axel De Muyt, general manager & VP of Novo Nordisk Belgium and Luxembourg, recounts his journey through the pharma industry, how he has been able to revive the company’s perspectives…
In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy Zolgensma® for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA)…
GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries in the effort to develop a safe, effective, and mass-producible COVID-19 vaccine. PharmaBoardroom…
Alexander Alonso, general manager of medtech giant BD’s operations in Belgium, the Netherlands, and Luxembourg outlines the company’s extensive footprint in the region, how it has rapidly mobilised in the…
Philippe de Pougnadoresse, country president & general manager pharma for Novartis Belgium & Luxembourg, outlines his affiliate’s fast and comprehensive response to the COVID-19 crisis, what can be learned from…
Vincent Stephenne, managing director of Belgian CDMO BePharBel Manufacturing, highlights the company’s innovative approach to developing new galenic forms for existing molecules, its growth trajectory thus far, and his future…
Christophe Van Damme, vice president and general manager of Perrigo Belgium and Luxembourg, shines a light on the transformation for Perrigo since its acquisition of Omega Pharma in 2015. Van…
See our Cookie Privacy Policy Here
